UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.67-0.02 (-0.21%)
As of 03:16PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • W
    William H.
    $CARA Competitive Advantage-- only non addictive opioid -no drug interaction-anti pain anti pruritic action-no suppression of immune system for effect--only FDA approved drug for pruritus in dialysis -secure 2 yr TDAPA payment of $10500 in USA -world wide marketing partners -approved in Europe--Developing oral for multiple pruritus diseases
  • C
    Chris
    Well one year now since FDA approved IV Korsuva and still no sign of any use of the drug anywhere in the country. At this rate their patent will expire before they sell a single dose.
  • W
    William H.
    CARA still follows marijuana stocks MJ TOKE etfs as examples check their chart correlations --
    Also the market may think that some of the biologics that suppress the immune system to control Atopic Dermatitis will take the market away from Korsuva. This is false due to the risks(cancer infection etc.) that biologics carry and are used with severe cases of AD only
  • P
    Plotzke
    CARA looks like it is about to drop. Be careful guys. I have been reading www.daytradercompany.tech and their stocks have been doing way better.
  • B
    Ben
    Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

    Sep 08, 2022
    Download PDF
    – Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) –

    – Significant reduction of itch intensity was evident at Day 1 and effect was maintained through Week 8 –

    – Significantly greater proportion of patients who received oral difelikefalin vs. placebo achieved a complete response in WI-NRS at Week 8 –

    STAMFORD, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in notalgia paresthetica (NP). The data will be presented today by Mark Lebwohl, M.D., the lead investigator and Professor and Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, during a late-breaking news session at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

    The presentation includes data from 125 patients with NP and moderate-to-severe pruritus who were randomized to receive oral difelikefalin 2 mg twice daily or placebo over an 8-week treatment period.

    The primary efficacy endpoint of change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8 was achieved (-4.0 difelikefalin vs. -2.4 placebo, p=0.001). A statistically significant reduction in itch intensity was observed with oral difelikefalin at Day 1 compared to placebo and the effect was maintained through Week 8.

    Other endpoints included a ≥4-point improvement in WI-NRS, complete response in WI-NRS and safety assessments. A significantly greater proportion of patients achieved a ≥4-point improvement in WI-NRS score at Week 8 with oral difelikefalin vs. placebo (41% difelikefalin vs. 18% placebo, p=0.007). In addition, oral difelikefalin met the complete response endpoint, defined as a WI-NRS score of 0 or 1 for 70% of the daily non-missing WI-NRS scores for the week. At Week 8, a significantly greater proportion of patients receiving oral difelikefalin vs. placebo achieved a complete response (22% difelikefalin vs. 5% placebo, p<0.01).

    Oral difelikefalin was generally well tolerated, with all adverse events in difelikefalin-treated patients reported as mild or moderate in severity. Nausea, headache, dizziness, constipation, and increased urine output were more commonly reported in patients on difelikefalin.
  • l
    louthain
    Not sure what I would do with (http://marketdelving.com)! Their daily emails keep me up to date on the best stocks to watch and have made all the difference for me as an investor!
  • C
    Chris
    Watch out for the Fed rate hike coming. It's not going to be good for the stock market.
  • c
    charles
    now cara is going after japan with korsuva, might as well
  • B
    BURUCA
    The market is about to get crushed...Are you prepared? do this now. Check out http://cryptosecret.tech/
  • J
    Jeffrey
    Yes Ben big bucks
  • D
    Dainty
    CARA looks like it is about to drop. Be careful guys. I have been reading (http://Achieverspot.tech) and their stocks have been doing way better.
  • C
    Chris
    16 of the 22 posts made here this month are spam. Kind of sums up the interest in this company right now.
  • H
    Hadrava
    I don’t know how I ever traded without using (http://bullishstocks.tech) I look forward to their daily emails each morning that list pre-market movers based on thoroughly researched stock market and world news. I highly recommend anyone who invests in the stock market!
  • J
    Jeffrey
    And by the way if all of us who have been long with CARA make a ton of money guess what? WE ALL DESERVE IT - the amount of stress , disappointment and general "ups and downs" with this stock had all of us paying our dues and if anyone utters the words " you people were just lucky" I will scream .
  • J
    Jeffrey
    No volume
    No interest
    No big deal
  • W
    William H.
    It is estimated that pruritus affects 20% of the population or 66 million in the population at sometime. NP affects 8% of this portion or 5.3 million of the population in USA--Oral Korsuva will have a large market
  • J
    Jeffrey
    What do we need ?
    Revenue
    Revenue
    Revenue
  • J
    Jeffrey
    I read on "seeking alpha" that although risky patience will be critical - the writer basically said Cara needs a 3-5 year time frame . If you can stand the risk and committing money for up to 5 years you COULD be a very happy person but there still is risk -
  • B
    Ben
    Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022...More markets=more sales ;)